P. Brent Ferrell

2.4k total citations
49 papers, 1.1k citations indexed

About

P. Brent Ferrell is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, P. Brent Ferrell has authored 49 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 19 papers in Molecular Biology and 14 papers in Genetics. Recurrent topics in P. Brent Ferrell's work include Acute Myeloid Leukemia Research (33 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers) and Single-cell and spatial transcriptomics (9 papers). P. Brent Ferrell is often cited by papers focused on Acute Myeloid Leukemia Research (33 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers) and Single-cell and spatial transcriptomics (9 papers). P. Brent Ferrell collaborates with scholars based in United States, Canada and France. P. Brent Ferrell's co-authors include Howard L. McLeod, Jonathan M. Irish, Kirsten E. Diggins, Douglas B. Johnson, Eng M. Tan, Gary R. Pearson, Allison R. Greenplate, Zhuoyan Li, Mary Philip and Arissa Young and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

P. Brent Ferrell

45 papers receiving 1.1k citations

Peers

P. Brent Ferrell

IMMUN

HEMAT

ONCOL

PHARM

Philipp Haselmayer Germany

María José Arcos Spain

Carsten Grüllich Germany

Robert E. Ettlinger United States

Masato Yagita Japan

Jae‐Yong Kwak South Korea

Minh Diem Vu United States

Michael Binks United Kingdom

Lyle L. Sensenbrenner United States

A.B. Gottlieb United States

Philipp Haselmayer Germany

P. Brent Ferrell

482 ×1.4

IMMUN

220 ×0.7

152 ×0.5

HEMAT

106 ×0.4

ONCOL

27 ×0.1

PHARM

Citations per year, relative to P. Brent Ferrell P. Brent Ferrell (= 1×) peers Philipp Haselmayer

Countries citing papers authored by P. Brent Ferrell

Since Specialization

Citations

This map shows the geographic impact of P. Brent Ferrell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Brent Ferrell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Brent Ferrell more than expected).

Fields of papers citing papers by P. Brent Ferrell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Brent Ferrell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Brent Ferrell. The network helps show where P. Brent Ferrell may publish in the future.

Co-authorship network of co-authors of P. Brent Ferrell

This figure shows the co-authorship network connecting the top 25 collaborators of P. Brent Ferrell. A scholar is included among the top collaborators of P. Brent Ferrell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Brent Ferrell. P. Brent Ferrell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cortes, Jörge E., Gail J. Roboz, Maria R. Baer, et al.. (2025). Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. Journal of Hematology & Oncology. 18(1). 7–7. 7 indexed citations

Kim, Christina, et al.. (2025). IFNγ signaling drives resistance to FLT3 inhibition in acute myeloid leukemia. iScience. 28(12). 114079–114079.

Botton, Stéphane de, et al.. (2024). Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.. Journal of Clinical Oncology. 42(16_suppl). 6527–6527. 1 indexed citations

Heimlich, J. Brett, Alyssa Parker, Caitlyn Vlasschaert, et al.. (2024). Multiomic profiling of human clonal hematopoiesis reveals genotype and cell-specific inflammatory pathway activation. Blood Advances. 8(14). 3665–3678. 19 indexed citations

Parker, Alyssa, J. Brett Heimlich, Yash Pershad, et al.. (2024). Methylation sequencing enhances interpretation of clonal hematopoiesis dynamics. Blood. 145(9). 988–992.

Welner, Robert S., et al.. (2024). Distinct Transcriptomic Cell States Differentiate Low-Risk MDS from Healthy Marrow. Blood. 144(Supplement 1). 1814–1814. 1 indexed citations

Kishtagari, Ashwin, Yajing Li, Caitlyn Vlasschaert, et al.. (2024). Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk. Blood Cancer Journal. 14(1). 6–6. 4 indexed citations

Cortes, Jörge E., Joseph G. Jurcic, Maria R. Baer, et al.. (2023). Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax. Blood. 142(Supplement 1). 2888–2888. 4 indexed citations

Ramsey, Haley E., Phuong Nguyen, Andrew R. Patterson, et al.. (2022). Acly Deficiency Enhances Myelopoiesis through Acetyl Coenzyme A and Metabolic–Epigenetic Cross-Talk. ImmunoHorizons. 6(12). 837–850. 3 indexed citations

10.

Arrate, Maria P., Haley E. Ramsey, Tamara K. Moyo, et al.. (2021). The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib. Experimental Hematology. 97. 57–65.e5. 2 indexed citations

11.

Guo, Hui, Haley E. Ramsey, Bradley I. Reinfeld, et al.. (2021). Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase. Nature Chemical Biology. 18(4). 360–367. 24 indexed citations

12.

Li, Zhuoyan, Mary Philip, & P. Brent Ferrell. (2020). Alterations of T-cell-mediated immunity in acute myeloid leukemia. Oncogene. 39(18). 3611–3619. 41 indexed citations

13.

Camacho, Virginia, Sweta B. Patel, Jeremie M. Lever, et al.. (2020). Bone marrow Tregs mediate stromal cell function and support hematopoiesis via IL-10. JCI Insight. 5(22). 34 indexed citations

14.

Davis, Elizabeth J., Joe‐Elie Salem, Arissa Young, et al.. (2019). Hematologic Complications of Immune Checkpoint Inhibitors. The Oncologist. 24(5). 584–588. 115 indexed citations

15.

Greenplate, Allison R., Deon B. Doxie, Kirsten E. Diggins, et al.. (2018). Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. Cancer Immunology Research. 7(1). 86–99. 21 indexed citations

16.

Cortes, Jörge E., Justin M. Watts, Thomas Prébet, et al.. (2018). FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study. Blood. 132(Supplement 1). 1452–1452. 14 indexed citations

17.

Strickland, Stephen A., Aaron C. Shaver, Michael Byrne, et al.. (2018). Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. Leukemia Research. 65. 67–73. 10 indexed citations

18.

Ferrell, P. Brent, et al.. (2018). Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes. Current Hematologic Malignancy Reports. 13(4). 244–255. 25 indexed citations

19.

Greenplate, Allison R., Douglas B. Johnson, Mikaël Roussel, et al.. (2016). Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti–PD-1 Therapy. Cancer Immunology Research. 4(6). 474–480. 16 indexed citations

20.

Ferrell, P. Brent, Kirsten E. Diggins, Hannah G. Polikowsky, et al.. (2016). High-Dimensional Analysis of Acute Myeloid Leukemia Reveals Phenotypic Changes in Persistent Cells during Induction Therapy. PLoS ONE. 11(4). e0153207–e0153207. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact